Protocols for High-Risk Pregnancies. Группа авторов
as analgesics, employed for the treatment of opioid use disorder, and available in illicit economies (heroin and both diverted and counterfeit pills). Although data support the use of opioids for acute pain, their effectiveness for chronic pain management is limited. Details regarding opioid prescribing for pain are beyond the scope of this Protocol though general principles of care include (i) treating pain with combination therapies (both opioid and nonopioid pharmaceuticals and nonpharmacologic management), and (ii) when opioids must be used, employ the lowest dose for the shortest duration.
Risks associated with opioid use include (i) tolerance (dose increase needed to maintain effect), (ii) dependence (withdrawal symptoms upon cessation), and (iii) overdose‐related morbidity and mortality. The risk of overdose is related not just to the opioid dose, but also to the concomitant use of other central nervous system (CNS) depressants (both prescribed and not prescribed) such as benzodiazepines, zolpidem and other sleep aids and alcohol. Therefore, individuals prescribed opioids for both chronic pain and addiction treatment should be co‐prescribed naloxone and instructed in its use. Naloxone is an opioid antagonist, most often administered via an intranasal route, which reverses opioid overdose.
A third of individuals prescribed opioids for chronic pain report misuse. Symptoms of misuse can include taking extra medication because of the effect, running out of prescriptions early, and crushing and snorting or injecting the medication. At most, 12% of individuals prescribed opioids for chronic pain develop an opioid use disorder. Opioid misuse can be a risk factor for the development of opioid addiction. Validated instruments, such as the Opioid Risk Tool, should be utilized when initiating opioid prescribing to assess and communicate misuse and addiction risk to patients.
Screening and diagnosis
Pregnancy is an opportune time to assess behavioral health conditions in general, and substance use and addiction in particular. Universal screening with a validated instrument is recommended as a routine part of prenatal care. The following instruments have been studied in a comparative study design: the Substance Use Risk Profile‐Pregnancy (SURP‐P), CRAFFT, 5Ps (parents, peers, partner, pregnancy, past), Wayne Indirect Drug Use Screener (WIDUS) and the National Institute on Drug Abuse (NIDA) Quick Screen. All perform with similar efficacy though none has both high sensitivity and high specificity. Screening should occur at the first prenatal care visit, every trimester, and, especially, postpartum. Urine drug testing is not a substitute for screening. Urine drug tests, especially point‐of‐care tests, do not capture certain substances (such as alcohol, nicotine and many synthetic opioids including fentanyl) and are plagued by false‐positive results due to medications commonly utilized in pregnancy and during labor and delivery.
Most people who use substances quit or cut back during pregnancy. However, some people cannot, most likely because they have an addiction. While it is very rare for a woman to develop an addiction during pregnancy, some people with addiction get pregnant and may initially present for care during pregnancy. Opioid addiction (also termed opioid use disorder) is a chronic and treatable disease. Symptoms of addiction include inordinate amount of time spent craving, obtaining, using, and recovering from a substance; compulsive use; use that interferes with school, job, family, and other aspects of social life; and continued use despite harms to self and others. Opioid addiction should be diagnosed with the framework detailed in the DSM‐5.
Management
Individuals with addiction need treatment. The core component of opioid addiction treatment is medication. There are three FDA‐approved medications for opioid use disorder: methadone, buprenorphine, and naltrexone. Evidence for naltrexone in pregnancy is limited and therefore it is not recommended at this time. Methadone, a full opioid agonist, has been used in pregnancy since the 1960s and buprenorphine has been available in the US since 2002. Randomized trial and systematic review data demonstrate that both are safe and effective. Methadone must be dispensed from an opioid treatment program (OTP) and carries a small risk of overdose primarily during the initial phase of treatment. Buprenorphine can be dispensed from an OTP but is more often prescribed by providers who have obtained an “X waiver” from the Drug Enforcement Administration (DEA). Buprenorphine is a partial agonist and can precipitate withdrawal if given to a patient who is not already in withdrawal. Neonatal abstinence syndrome (NAS) is a possible side effect of both methadone and buprenorphine, although the severity and duration of NAS are less with buprenorphine.
Patients can be initiated on medication in either inpatient or outpatient settings at any gestational age. Both methadone and buprenorphine can be administered in inpatient settings by providers without DEA X waivers and by health systems without attached OTPs. Details regarding medication choice are detailed in Table 3.1. However, the hospital care team must ensure presence and availability of outpatient providers for continuing care.
Initial clinical assessment should include a Clinical Opiate Withdrawal Scale (COWS), other substance use history, and HIV and HCV testing. COWS is an 11‐item scale administered by a clinician which provides a summary measure of withdrawal. (There is a helpful online tool to assess COWS available at: www.mdcalc.com/cows‐score‐opiate‐withdrawal). Medication dosage is first titrated to treat withdrawal (see Table 3.2 for draft induction protocol). Stabilization occurs within days. Further dose increases may be needed to control craving. A goal of medication‐assisted treatment for opioid addiction is a clinically meaningful opioid “blockade”: the degree to which medications block the reinforcing effects of other self‐administered opioids. In other words, if a patient feels an effect from an opioid while receiving medication for opioid addiction, then a dose increase may be indicated.
Table 3.1 Medication choice for treatment of opioid use disorder in pregnancy and postpartum
| Benefit | Consideration | |
|---|---|---|
| Methadone | No need for withdrawal for initiation May have better treatment adherence | Must be dispensed from an opioid treatment programRisk of overdose if rapid initial titration |
| Buprenorphine | Can be prescribed by waivered provider Newborns may have less severe neonatal abstinence syndrome | Risk of precipitated withdrawal |
Table 3.2 Buprenorphine initiation protocol example
Source: Based on Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35(2):253–9.
| Day 1:Document baseline Clinical Opiate Withdrawal Scale (COWS)Administer buprenorphine/naloxone (SL)aCOWS 8‐10: Give buprenorphine/naloxone 2/0.5 mgCOWS >10: Give buprenorphine/naloxone 4/1 mgRepeat COWS in 1–2 hours and repeat administration of buprenorphine as aboveTypical day 1 dose = 6–8 mg |
| Day 2:Administer COWS and total day 1 buprenorphineRepeat COWS in 1–2 hours and administer additional buprenorphine as aboveTypical day 2 dose = 8–16 mg |
Medication for opioid addiction works. Recurrence rates for treated addiction are similar to other chronic conditions such as hypertension. Furthermore, much of the obstetric burden from substance use is from